Based on overall chemical stability, efficacy, negligible cardiovascular effects, and onset profiles, ATLX-0199 (D-Cystine diME) was selected as the lead compound for clinical development, with back-up compounds available.  ATLX-0199 safely stimulates opioid-depressed respiratory drive without interfering with opioid-induced analgesia.